tirofiban Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
fibrinogen receptor antagonists (glycoprotein IIb/IIIa receptor antagonists) 2680 144494-65-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tirofiban
  • aggrestat
  • tirofiban hydrochloride
  • tirofiban HCl
  • tirofiban hydrochloride monohydrate
  • L-700,462
  • aggrastat
a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation, when administered intravenously inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner
  • Molecular weight: 440.60
  • Formula: C22H36N2O5S
  • CLOGP: 2
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 104.73
  • ALOGS: -5.14
  • ROTB: 13

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 65 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.34 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.36 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 14, 1998 FDA MEDICURE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 104.85 88.24 41 442 138686 53209897

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 245.23 54.33 108 880 148191 32364347
Cerebral haemorrhage 65.21 54.33 28 960 34719 32477819
Cardiogenic shock 64.35 54.33 24 964 20638 32491900
Vascular stent thrombosis 58.95 54.33 14 974 2533 32510005

Pharmacologic Action:

SourceCodeDescription
ATC B01AC17 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA PE N0000008832 Decreased Platelet Aggregation
FDA EPC N0000175578 Platelet Aggregation Inhibitor
MeSH PA D002317 Cardiovascular Agents
MeSH PA D005343 Fibrinolytic Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:48676 fibrin modulating agents
CHEBI has role CHEBI:50249 anticoagulante
CHEBI has role CHEBI:50433 platelet glycoprotein-IIb/IIIa receptor antagonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-Q wave myocardial infarction indication 314207007
Acute coronary syndrome indication 394659003
Percutaneous coronary intervention indication 415070008
Intracranial hemorrhage contraindication 1386000
Acute pericarditis contraindication 15555002
Arteriovenous malformation contraindication 24551003
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Neoplasm of brain contraindication 126952004 DOID:1319
Bleeding contraindication 131148009
Lithotripsy contraindication 133864008
Cerebrovascular accident contraindication 230690007
Arterial aneurysm contraindication 233981004
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Dissection of aorta contraindication 308546005
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Hypertensive urgency contraindication 443482000
Hemorrhagic Diabetic Retinopathy contraindication
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.02 acidic
pKa2 13.5 acidic
pKa3 10.31 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) AGGRASTAT MEDICURE N020912 May 14, 1998 DISCN INJECTABLE INJECTION 6770660 May 1, 2023 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) AGGRASTAT MEDICURE N020912 Aug. 31, 2016 RX SOLUTION INJECTION 6770660 May 1, 2023 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) AGGRASTAT MEDICURE N020913 April 20, 2000 RX SOLUTION INTRAVENOUS 6770660 May 1, 2023 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML) AGGRASTAT MEDICURE N020913 May 14, 1998 DISCN SOLUTION INTRAVENOUS 6770660 May 1, 2023 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) AGGRASTAT MEDICURE N020913 May 17, 2002 RX SOLUTION INTRAVENOUS 6770660 May 1, 2023 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-IIb/beta-3 Adhesion INHIBITOR IC50 7.96 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
4024116 VUID
N0000022121 NUI
D01029 KEGG_DRUG
150915-40-5 SECONDARY_CAS_RN
4021109 VANDF
4024116 VANDF
C0247025 UMLSCUI
CHEBI:9605 CHEBI
AGG PDB_CHEM_ID
CHEMBL916 ChEMBL_ID
CHEMBL3189072 ChEMBL_ID
CHEMBL1704 ChEMBL_ID
D000077466 MESH_DESCRIPTOR_UI
DB00775 DRUGBANK_ID
6586 IUPHAR_LIGAND_ID
7345 INN_ID
GGX234SI5H UNII
60947 PUBCHEM_CID
187024 RXNORM
11701 MMSL
5588 MMSL
d04315 MMSL
007531 NDDF
108981004 SNOMEDCT_US
386953003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
AGGRASTAT HUMAN PRESCRIPTION DRUG LABEL 1 25208-001 INJECTION, SOLUTION 3.75 mg INTRAVENOUS NDA 25 sections
AGGRASTAT HUMAN PRESCRIPTION DRUG LABEL 1 25208-002 INJECTION, SOLUTION 5 mg INTRAVENOUS NDA 25 sections
Tirofiban hydrochloride Human Prescription Drug Label 1 68083-145 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 25 sections